Should I invest in Nippon India Nifty Pharma ETF?

We don't give personal investment advice. Nippon India Nifty Pharma ETF is suitable for an investor whose:understands what asset class this scheme actually invests in (check the factsheet)matches that asset class's volatility profile to their goal horizonCross-check the numbers above against alternatives before deciding. Worst 5-year drawdown: 21.0%. 5-year CAGR: 12.42%.

Nippon India

Nippon India Nifty Pharma ETF

Latest NAV

₹26.3588

As of

17 Jul 2026

1,243 NAV records on file

NAV history & peer comparison

All NAVs split-adjusted and normalised to 100 at the start of the selected period, so funds with very different absolute NAV scales can be compared on one axis.

Period

Add another fund to compare

No matches.

Compares up to 8 funds. Click any line in the legend above to hide/show it.

Returns matrix

Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).

Window	Fund	Category avg	+/− vs avg	Rank	Quartile
1D	-1.35%	+0.27%	-1.62	274 / 280	Q4
1W	-0.08%	-0.11%	+0.02	130 / 280	Q2
2W	-0.26%	-0.16%	-0.09	181 / 280	Q3
1M	+6.34%	-0.09%	+6.43	5 / 280	Q1
3M	+14.21%	+0.82%	+13.40	4 / 272	Q1
6M	+15.85%	-1.65%	+17.50	8 / 261	Q1
YTD	+13.71%	-1.34%	+15.05	10 / 258	Q1
1Y	+13.62%	+7.47%	+6.15	34 / 231	Q1
2Y	+11.65%	+4.66%	+6.99	24 / 185	Q1
3Y	+22.91%	+12.66%	+10.25	18 / 149	Q1
4Y	+19.80%	+14.72%	+5.08	26 / 126	Q1
5Y	+12.42%	+10.99%	+1.42	26 / 90	Q2
7Y	—	—	—	—	—
10Y	—	—	—	—	—
Inception	+12.75%	+10.92%	+1.83	90 / 280	Q2

Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%

Calendar-year returns

Full-year performance vs category average. Current year is partial (year-to-date).

Year	Fund	Category avg	+/− vs avg	Rank
2026 YTD	+13.71%	-1.36%	+15.07	10 / 257
2025	-2.65%	+16.95%	-19.61	171 / 192
2024	+39.37%	+15.68%	+23.69	6 / 155
2023	+35.16%	+24.57%	+10.59	25 / 133
2022	-10.86%	+3.53%	-14.39	92 / 104
2021	—	—	—	—

Rolling returns

Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.

1-Year rolling

+16.28%

50 windows

min -12.5% · max 62.1%

72% positive

Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.

3-Year rolling

+20.68%

25 windows

min 16.3% · max 27.5%

100% positive

Limited basis — fund is young, so this average may be skewed by which 3Y windows happen to be available.

5-Year rolling

+12.42%

1 window

min 12.4% · max 12.4%

100% positive

Limited basis — fund is young, so this average may be skewed by which 5Y windows happen to be available.

7-Year rolling

—

Insufficient history

SIP returns — historical "what if"

If you had invested every month in this fund over the chosen period, this is what your investment would be worth today.

Period

Total invested

₹ —

Today's value

₹ —

XIRR

Annualised

Wealth multiplier

Period	Total invested	Today's value	XIRR	Wealth multiplier

XIRR is the annualised internal rate of return on the SIP cash flow — invariant to the monthly amount. "Today's value" and "Total invested" scale linearly with the slider. Past performance does not guarantee future returns. Excludes exit load and taxes.

Risk profile

Risk-adjusted return and volatility, computed from monthly NAV returns over the trailing 3-year and 5-year windows.

Std deviation

13.47%

3-year · annualised

Sharpe ratio

1.12

vs risk-free 6.5%

Sortino ratio

2.68

Downside-only deviation

Max drawdown

-16.55%

Oct 2024 → Feb 2025

% positive months

61.1%

Share of monthly returns > 0 over the 3-year window

Sharpe / Sortino use a risk-free rate of 6.5% (1-year T-bill proxy). Higher Sharpe = more return per unit of total risk; higher Sortino = more return per unit of downside risk.

Peers in ETF

Scheme	Fund house	NAV	As of
HDFC NIFTY PSU BANK ETF	HDFC	₹84.8548	17 Jul 2026
Nippon India ETF Nifty Bank BeES	Nippon India	₹605.9020	17 Jul 2026
SBI BSE PSU BANK ETF	SBI	₹48.4663	17 Jul 2026
ICICI Prudential Nifty Auto ETF	ICICI Prudential	₹28.0218	17 Jul 2026
Aditya Birla Sun Life Nifty Bank ETF	Aditya Birla Sun Life	₹59.9924	17 Jul 2026
Motilal Oswal BSE Healthcare ETF	Motilal Oswal	₹50.5040	17 Jul 2026
Mirae Asset BSE India Defence ETF	Mirae Asset	₹77.7638	17 Jul 2026
Kotak Nifty Bank ETF	Kotak	₹60.7355	17 Jul 2026
Kotak PSU Bank ETF	Kotak Mahindra	₹83.9800	17 Jul 2026
DSP Nifty Bank ETF	DSP	₹59.9059	17 Jul 2026

Recent NAVs

Date	NAV
17 Jul 2026	₹26.3588
16 Jul 2026	₹26.7192
15 Jul 2026	₹26.7182
14 Jul 2026	₹26.6194
13 Jul 2026	₹26.3490
10 Jul 2026	₹26.3809
9 Jul 2026	₹26.3491
8 Jul 2026	₹26.1169
7 Jul 2026	₹26.3714
6 Jul 2026	₹26.5501

Frequently asked questions

These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.

As of 17 Jul 2026, the NAV of Nippon India Nifty Pharma ETF is ₹26.3588. It's a ETF from Nippon India, run as a Unknown plan IDCW (dividend) option. NAVs update once per business day from the AMFI feed.

Nippon India Nifty Pharma ETF has NAV history starting from 06 Jul 2021, a track record of about 5 years. That's enough history to evaluate the fund across one or two market cycles. Look at rolling returns rather than point-to-point to judge consistency.

Nippon India Nifty Pharma ETF is managed by Nippon India. It's classified by AMFI under the 'ETF' SEBI category, which determines its peer set and tax treatment.

Over the trailing 1-year window, Nippon India Nifty Pharma ETF has delivered a absolute return of 13.62% — +6.15 pp ahead of the ETF category average of 7.47%. The fund ranks #34 of 231 in its category — the top (Q1) quartile.

Over the trailing 3-year window, Nippon India Nifty Pharma ETF has delivered a CAGR of 22.91% — +10.25 pp ahead of the ETF category average of 12.66%. The fund ranks #18 of 149 in its category — the top (Q1) quartile.

Over the trailing 5-year window, Nippon India Nifty Pharma ETF has delivered a CAGR of 12.42% — +1.42 pp ahead of the ETF category average of 10.99%. The fund ranks #26 of 90 in its category — the second (Q2) quartile.

₹1 lakh invested in Nippon India Nifty Pharma ETF exactly 5 years ago would be worth approximately ₹179,524 today — a multiplier of 1.80×, based on the 5-year CAGR of 12.42%. The category average over the same window would have grown ₹1 lakh to ₹168,459.

A ₹10,000 monthly SIP in Nippon India Nifty Pharma ETF over the last 5 years — total invested ₹600,000 — would be worth ₹943,920 today. That's an XIRR (money-weighted annualised return) of 18.17%.

Nippon India Nifty Pharma ETF doesn't yet have 10 years of NAVs. Over the longest available window (5-year SIP), ₹10,000/month would have grown to ₹943,920 — XIRR 18.17%.

On a 5-year basis, Nippon India Nifty Pharma ETF ranks #26 out of 90 funds in the ETF category — that places it in the second quartile (Q2) — above the median. The category average return over the same window is 10.99%; this fund delivered 12.42%.

The worst peak-to-trough decline Nippon India Nifty Pharma ETF has experienced over the last 5-year window is 20.98% — its NAV fell from a high on 04 Oct 2021 to a low on 13 Mar 2023. Drawdown is a useful gauge of how much short-term pain you'd have endured to capture the long-term return.

Across all 5-year rolling windows, Nippon India Nifty Pharma ETF averaged 12.42% (best 12.42%, worst 12.42%). 100% of rolling windows ended positive. The 5-year Sharpe ratio is 0.43 — weak risk-adjusted performance.

In calendar year 2025, Nippon India Nifty Pharma ETF returned -2.65% — lagging the ETF category average of 16.95% by 19.61 pp. It ranked #171 of 192 in its category that year.

Nippon India Nifty Pharma ETF doesn't fit cleanly into the standard Equity/Debt buckets in our taxonomy. Tax treatment depends on actual asset allocation as disclosed by the AMC — check the factsheet or AMFI's classification table.

We don't give personal investment advice. Nippon India Nifty Pharma ETF is suitable for an investor whose:

understands what asset class this scheme actually invests in (check the factsheet)
matches that asset class's volatility profile to their goal horizon

Cross-check the numbers above against alternatives before deciding. Worst 5-year drawdown: 21.0%. 5-year CAGR: 12.42%.

Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.